Gillis R A, Gatti P J, Quest J A
J Cardiovasc Pharmacol. 1985;7 Suppl 8:S38-44.
Drugs such as clonidine, methyldopa, guanabenz, guanfacine, and lofexidine have their primary site of antihypertensive action in the central nervous system (CNS) to activate alpha 2-adrenergic receptors and lower arterial pressure. The most probable CNS site of action of these drugs is the medulla oblongata at a post-synaptic location. Current evidence indicates that within the medulla, the prototype drug, clonidine, most likely acts at the lateral reticular nucleus. This site is the most sensitive in terms of hypotension occurring after microinjection of clonidine. In addition, lesion of this nucleus abolishes the hypotensive effect of systemically administered clonidine. Recently, a clonidine-displacing endogenous brain substance has been isolated and partially purified from calf brain. Knowledge of where clonidine acts to lower blood pressure should help in assessing the role of an endogenous clonidine-displacing substance in CNS control of cardiovascular function.
可乐定、甲基多巴、胍那苄、胍法辛和洛非西定等药物的主要降压作用部位在中枢神经系统(CNS),可激活α2-肾上腺素能受体并降低动脉血压。这些药物最可能的CNS作用部位是延髓的突触后位置。目前的证据表明,在延髓内,原型药物可乐定最有可能作用于外侧网状核。就可乐定微量注射后出现的低血压而言,该部位最为敏感。此外,损毁该核可消除全身给药可乐定的降压作用。最近,已从小牛脑中分离并部分纯化出一种可取代可乐定的内源性脑物质。了解可乐定降压的作用部位应有助于评估内源性可乐定取代物质在CNS对心血管功能控制中的作用。